Advanced search
Publication Cover
Pain Management Volume 11, 2021 - Issue 3
Submit an article Journal homepage
140
Views
0
CrossRef citations to date
0
Altmetric
Case Series

Subanesthetic Ketamine in the Ambulatory Setting for Refractory Cancer Pain: A 6-Year Retrospective at a Cancer Center

Matthew Chung1 Department of Pain Medicine, Division of Anesthesiology, Critical Care & Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX77030, USACorrespondence[email protected]
,
Barlas Benkli2 Department of Neurology, The University of Texas McGovern Medical School, Houston, TX 77030, USA
,
Carlos Roldan1 Department of Pain Medicine, Division of Anesthesiology, Critical Care & Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX77030, USA;3 McGovern Medical School at the University of Texas Health Science, Houston, TX77030, USA
,
Yun Qing4 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX77030, USA
,
Jian Wang4 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX77030, USA
&
Billy Huh1 Department of Pain Medicine, Division of Anesthesiology, Critical Care & Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX77030, USA
Pages 267-276 | Received 29 Sep 2020, Accepted 07 Jan 2021, Published online: 03 Feb 2021

References

  • Jacobs M , MacefieldRC , ElbersRGet al. Meta-analysis shows clinically relevant and long-lasting deterioration in health-related quality of life after esophageal cancer surgery. Qual. Life Res.23(4), 1097–1115 (2014).
  • van den Beuken-van Everdingen MHJ , de RijkeJM , KesselsAG , SchoutenHC , van KleefM , PatijnJ. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain132(3), 312–320 (2007).
  • Afsharimani B , KindlK , GoodP , HardyJ. Pharmacological options for the management of refractory cancer pain – what is the evidence?Support. Care Cancer23(5), 1473–1481 (2015).
  • Fallon MT . Neuropathic pain in cancer. Br. J. Anaesth.111(1), 105–111 (2013).
  • Peltoniemi MA , HagelbergNM , OlkkolaKT , SaariTI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin. Pharmacokinet.55(9), 1059–1077 (2016).
  • Shteamer JW , HarveyRD , SpektorBet al. Safety of intranasal ketamine for reducing uncontrolled cancer-related pain: protocol of a Phase I/II clinical trial. JMIR Res. Protoc.8(4), e12125 (2019).
  • Singh V , GillespieTW , HarveyRD. Intranasal ketamine and its potential role in cancer-related pain. Pharmacother. J. Hum. Pharmacol. Drug Ther.38(3), 390–401 (2018).
  • Assouline B , TramèrMR , KreienbühlL , EliaN. Benefit and harm of adding ketamine to an opioid in a patient-controlled analgesia device for the control of postoperative pain. Pain157(12), 2854–2864 (2016).
  • Dahl JB , MooreRA , KalsoEA. Perioperative ketamine for acute postoperative pain. In: Cochrane Database of Systematic Reviews.BellRF ( Ed.). John Wiley & Sons, Ltd, Chichester, UK (2006).
  • Laskowski K , StirlingA , McKayWP , LimHJ. A systematic review of intravenous ketamine for postoperative analgesia. Can. J. Anesth. Can. d’anesthésie.58(10), 911–923 (2011).
  • Bell RF , KalsoEA. Ketamine for pain management. PAIN Reports.3(5), e674 (2018).
  • Fine PG . Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J. Pain Symptom Manag.17(4), 296–300 (1999).
  • Yang C-Y , WongC-S , ChangJ-Y , HoS-T. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can. J. Anaesth.43(4), 379–383 (1996).
  • Hardy J , QuinnS , FazekasBet al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J. Clin. Oncol.30(29), 3611–3617 (2012).
  • Mercadante S , ArcuriE , TirelliW , CasuccioA. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy. J. Pain Symptom Manag.20(4), 246–252 (2000).
  • Bell RF , EcclestonC , KalsoEA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst. Rev.6(6), CD003351 (2017).
  • Zgaia AO , IrimieA , SandescDet al. The role of ketamine in the treatment of chronic cancer pain. Med. Pharm. Rep.88(4), 457–461 (2015).
  • Cleeland C , RyanKM. Pain assessment: global use of the Brief Pain Inventory. Ann. Acad. Med. Singap.23(2), 129–138 (1994).
  • Hui D , BrueraE. The Edmonton symptom assessment system 25 years later: past, present, and future developments. J. Pain Symptom Manag.53(3), 630–643 (2017).
  • Michelet D , BrasherC , HorlinA-Let al. Ketamine for chronic non-cancer pain: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur. J. Pain22(4), 632–646 (2018).
  • Patil S , AnitescuM. Efficacy of outpatient ketamine infusions in refractory chronic pain syndromes: a 5-year retrospective analysis. Pain Med.13(2), 1526–4637 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.